Live market news
Stocks
PCVX

Vaxcyte Inc

PCVXStockUSA

See in Charts

Latest news on PCVXranked by Oyticker for market impact

75Impact
NeutralMajor information4 Oct 2026 · 21:00 UTC · Global · Immediate
Vaxcyte to Present OPUS-1 Phase 3 Topline Data for VAX-31 Pneumococcal Vaccine
Vaxcyte will present topline results from OPUS-1, a pivotal Phase 3 trial of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, on October 5, 2026. The data readout addresses a key regulatory milestone for this vaccine program.
PCVXBiotechnologyVaccinesPharmaceuticals

SEC filings

What PCVX filed

All its filings

4 Nov 2026
Quarterly report (opens the document on sec.gov)10-Q
4 Nov 2026
Results announced (opens the document on sec.gov)8-K
9 Oct 2026
Material agreement (opens the document on sec.gov)8-K
New debt or obligation · Other event
5 Oct 2026
Investor communication (opens the document on sec.gov)8-K
Other event
3 Sept 2026
Executive or director change (opens the document on sec.gov)8-K
Investor communication
5 Aug 2026
Quarterly report (opens the document on sec.gov)10-Q
5 Aug 2026
Results announced (opens the document on sec.gov)8-K
15 Jul 2026
Executive or director change (opens the document on sec.gov)8-K
23 Jun 2026
Executive or director change (opens the document on sec.gov)8-K
16 Jun 2026
Shareholder vote results (opens the document on sec.gov)8-K

From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.

Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.

Latest news on PCVXranked by Oyticker for market impact

Vaxcyte to Present OPUS-1 Phase 3 Topline Data for VAX-31 Pneumococcal Vaccine

What PCVX filed